

## Influenza A(H1N1)pdm09 egg-derived<sup>1</sup> candidate vaccine viruses for development and production of vaccines for use in the 2026-2027 northern hemisphere influenza season

Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise specified, all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test. [National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)<sup>2</sup>

**27 February 2026**

### Candidate vaccine viruses (CVVs) antigenically like A/Missouri/11/2025 (egg-derived) - Accession number (GISAID): EPI\_ISL\_20066835

Parent virus	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Missouri/11/2025	Wild Type		CDC	CDC
	<b>SAN-046</b>	Classical	Sanofi	Sanofi, USA
	<b>IVR-279</b>	Classical	Seqirus	MHRA
A/Switzerland/6849/2025	Wild Type		FCI	MHRA
	<b>IVR-278</b>	Classical	Seqirus	MHRA

#### Institutes contact details for candidate vaccine virus orders/information:

**CDC:** [cvvrequest@cdc.gov](mailto:cvvrequest@cdc.gov) (Subject: CVV request)

**MHRA:** [standards@mhra.gov.uk](mailto:standards@mhra.gov.uk) or [enquiries@mhra.gov.uk](mailto:enquiries@mhra.gov.uk)

**Sanofi:** [raymond.schwartz@sanofi.com](mailto:raymond.schwartz@sanofi.com)

**WHO CCs and ERLs:** [http://www.who.int/influenza/gisrs\\_laboratory/collaborating\\_centres](http://www.who.int/influenza/gisrs_laboratory/collaborating_centres)

<sup>1</sup> For cell-derived candidate vaccine viruses and reference reagents please see <https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>

<sup>2</sup> <https://www.who.int/initiatives/who-listed-authority-reg-authorities>

## Reference antigens (freeze dried) – to be updated

Parent virus	Starting materials		Ref Ag lot number	Unitage (µg HA/ml)	Available from
	Candidate vaccine virus	Egg or cell			
A/Switzerland/6849/2025	IVR-278	Egg	2025/154B	57	TGA, Australia
			H1-Ag-2513	50	CBER/FDA, USA
			25/222	54	MHRA, UK

## Sheep antisera – to be updated

Purified HA from	Egg or cell	Order lot number	Available from
Parent virus			
A/Missouri/11/2025-like	Egg	AS467	TGA, Australia
		25/224	MHRA, UK
		H1-Ab-2512	CBER/FDA, USA

WHO Essential Regulatory Laboratories (ERLs) contact details for reagent orders and other information:

**MHRA:** [standards@mhra.gov.uk](mailto:standards@mhra.gov.uk) or [enquiries@mhra.gov.uk](mailto:enquiries@mhra.gov.uk)

**NIID:** [flu-vaccine@nih.go.jp](mailto:flu-vaccine@nih.go.jp)

**TGA:** [influenza.reagents@tga.gov.au](mailto:influenza.reagents@tga.gov.au)

For reagents available from **CBER**, email [CBERShippingRequests@fda.hhs.gov](mailto:CBERShippingRequests@fda.hhs.gov).

For information of other type and subtype candidate vaccine viruses and potency testing reagents, please go to: (<https://www.who.int/teams/global-influenza-programme/vaccines/who-recommendations/candidate-vaccine-viruses>).

For general enquiries, please contact [gisrs-whohq@who.int](mailto:gisrs-whohq@who.int)